Evaluate monthly for adverse effects. Intermittent therapy has not been evaluated. Transfer to other facilities is not necessary. Additional expert consultation from the National Jewish Hospital in Denver, the Centers for Disease Control and Prevention in Atlanta, local infectious disease experts, or the department of health may be useful. Dissemination is a concern.
Death is an unlikely outcome except in patients who are immunocompromised.
Monotherapy may potentially induce resistance. With treatment, reported prognosis is excellent. If the culture report arrives after discharge, however, evaluate the patient for possible disease. In most cases, the isolates represent laboratory contamination of submitted specimens. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997.